Portola Pharmaceuticals, Inc. (PTLA)

Oncology Corporate Profile

Stock Performance

53.8600
-0.2600

3 Month Stock History Chart

HQ Location

270 E. Grand Avenue
South San Francisco, CA 94080

Company Description

Portola Pharmaceuticals is focused on the development and commercialization of novel therapeutics to meet patient needs in thrombosis, other hematologic disorders and inflammation. Our current development-stage portfolio includes wholly-owned and partnered products. Portola's wholly-owned product candidate, cerdulatinib (PRT2070), is an orally available kinase inhibitor that uniquely inhibits two validated tumor proliferation pathways -- spleen tyrosine kinase (Syk) and janus kinase (JAK). It is currently being studied in patients with leukemias or lymphomas with a focus on genetically-defined subtypes, as well as in patients who have failed therapy due to relapse or acquired mutations.

Website: http://www.portola.com

Brand Generic Indication
Bevyxxa®betrixabanBevyxxa® is a factor Xa (FXa) inhibitor indicated for the prophylaxis of venous thromboembolim (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
cerdulatinib / PTR-2070dual tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.Chronic Lymphocytic Leukemia (CLL)II
cerdulatinib / PTR-2070dual tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.Non-Hodgkin's Lymphoma (NHL)I

View additional information on product candidates here »

Source: http://www.portola.com

Recent News Headlines

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/17/2017 06:19 am

8/17/2017 06:19 am

8/17/2017 06:19 am

8/17/2017 06:19 am

8/17/2017 06:19 am

8/17/2017 12:19 am

8/17/2017 12:19 am

8/17/2017 12:19 am

8/17/2017 12:19 am

8/16/2017 06:19 am

8/15/2017 06:19 am

8/15/2017 06:19 am

8/15/2017 06:19 am

8/15/2017 06:19 am

8/12/2017 06:21 am

8/12/2017 06:21 am

8/11/2017 06:19 am

8/10/2017 06:19 am

8/10/2017 12:19 am

8/9/2017 12:19 pm